Riccardo Perfetti

Riccardo Perfetti

Auto-generated profile, based on publicly available information

Riccardo Perfetti

Division of Endocrinology and Metabolism (H.H, R.P.), and Division of Cardiology (X.Z.), Cedars‐Sinai Medical Center, Los Angeles, California, and University of California Los Angeles (H.H., R.P.), Los Angeles, California

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2003 in Endocrinology
Verified
Journal Article
Closed access
LFLoredana Farilla
Loredana Farilla
ABAngela Bulotta
Angela Bulotta
BHBoaz Hirshberg
Boaz Hirshberg
SCSergio Li Calzi
Sergio Li Calzi
NKNasif Khoury
Nasif Khoury
RPRiccardo Perfetti
Riccardo Perfetti
The peptide hormone, glucagon-like peptide 1 (GLP-1), has been shown to increase glucose-dependent insulin secretion, enhance insulin gene transcription, expand islet cell mass, and inhibit beta-cell apoptosis in animal models of diabetes. The aim of the present study was to evaluate whether GLP-1 could improve function and inhibit apoptosis in freshly isolated human islets. Human islets were cultured for 5 d in the presence, or absence, of GLP-1 (10 nm, added every 12 h) and studied for viability and expression of proapoptotic (caspase-3) and antiapoptotic factors (bcl-2) as well as glucose-dependent insulin production. We observed better-preserved three-dimensional islet morphology in the GLP-1-treated islets, compared with controls. Nuclear condensation, a feature of cell apoptosis, was inhibited by GLP-1. The reduction in the number of apoptotic cells in GLP-1-treated islets was particularly evident at d 3 (6.1% apoptotic nuclei in treated cultures vs. 15.5% in controls; P < 0.01) and at d 5 (8.9 vs. 18.9%; P < 0.01). The antiapoptotic effect of GLP-1 was associated with the down-regulation of active caspase-3 (P < 0.001) and the up-regulation of bcl-2 (P < 0.01). The effect of GLP-1 on the intracellular levels of bcl-2 and caspase-3 was observed at the mRNA and protein levels. Intracellular insulin content was markedly enhanced in islets cultured with GLP-1 vs. control (P < 0.001, at d 5), and there was a parallel GLP-1-dependent potentiation of glucose-dependent insulin secretion (P < 0.01 at d 3; P < 0.05 at d 5). Our findings provide evidence that GLP-1 added to freshly isolated human islets preserves morphology and function and inhibits cell apoptosis.

3 February 2003 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Closed access
PDF file
JEJosephine M. Egan
Josephine M. Egan
ABAngela Bulotta
Angela Bulotta
HHHongxiang Hui
Hongxiang Hui
RPRiccardo Perfetti
Riccardo Perfetti

1 June 2002 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
HHH Hui
H Hui
LFL Farilla
L Farilla
PMP Merkel
P Merkel
RPR Perfetti
R Perfetti
The incretin hormone glucagon-like peptide-1 (GLP-1) is capable of ameliorating glucose-dependent insulin secretion in subjects with diabetes. However, its very short half-life (1.5-5 min) in plasma represents a major limitation for its use in the clinical setting. The present study was designed to characterize the duration of the effect of GLP-1 in the Zucker diabetic fatty (ZDF) rat. ZDF rats were subjected to a 48 h infusion of human GLP-1 (30 pmol/kg per min), followed by an i.p. glucose tolerance test (IPGTT) (1 g/kg body weight), 2 h after removing the infusion pump. At 15 min from the beginning of the test, GLP-1-treated animals had lower plasma glucose levels (442+/-38 mg/dl) than saline-infused controls (583+/-63 mg/dl, P<0.01). This was reflected in the higher insulin levels attained in the GLP-1-treated animals (1999+/-163 vs 1250+/-51 pmol/l, GLP-1 vs saline respectively, P<0.01). Repetition of the IPGTT on day 3, 9 and 16 from the removal of the infusion pump revealed a surprising lasting 'memory' of the exposure to GLP-1. Indeed, the best insulin secretory response was observed approximately 1 week after discontinuation of the GLP-1 infusion, and lasted up to 3 weeks from the early exposure to GLP-1. Detection of fasting plasma levels of GLP-1 during the 3 weeks of the experiment showed a very rapid decline, consistent with the data reported by others. Our findings provide evidence for a long-lasting beneficial effect of GLP-1 that persists for weeks even when the circulating levels of GLP-1 are back to normal.

1 December 2000 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
RPR Perfetti
R Perfetti
PMP Merkel
P Merkel
Glucagon-like peptide-1 (GLP-1) is a gut hormone synthesized by post-translational processing in intestinal L-cells, and it is released in response to food ingestion. GLP-1 stimulates insulin secretion during hyperglycemia, suppresses glucagon secretion, stimulates (pro)-insulin biosynthesis and decreases the rate of gastric emptying and acid secretion. GLP-1 has also been shown to have a pro-satiety effect. In addition, it has been demonstrated that a long-term infusion with GLP-1, or exendin-4, a long-acting analog of human GLP-1, increases beta-cell mass in rats. In conclusion, GLP-1 appears to regulate plasma glucose levels via various and independent mechanisms. GLP-1 is an excellent candidate option for the treatment of patients with type 2 diabetes mellitus.

27 May 2004 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
HHHongxiang Hui
Hongxiang Hui
FDFrancesco Dotta
Francesco Dotta
UMUmberto Di Mario
Umberto Di Mario
RPRiccardo Perfetti
Riccardo Perfetti

26 April 2005 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Closed access
PDF file
HHHongxiang Hui
Hongxiang Hui
XZXiaoning Zhao
Xiaoning Zhao
RPRiccardo Perfetti
Riccardo Perfetti